1. Home
  2. LPA vs ALDX Comparison

LPA vs ALDX Comparison

Compare LPA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPA
  • ALDX
  • Stock Information
  • Founded
  • LPA 2013
  • ALDX 2004
  • Country
  • LPA United States
  • ALDX United States
  • Employees
  • LPA N/A
  • ALDX N/A
  • Industry
  • LPA
  • ALDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LPA
  • ALDX Health Care
  • Exchange
  • LPA Nasdaq
  • ALDX Nasdaq
  • Market Cap
  • LPA 310.7M
  • ALDX 304.9M
  • IPO Year
  • LPA N/A
  • ALDX 2014
  • Fundamental
  • Price
  • LPA $9.20
  • ALDX $6.58
  • Analyst Decision
  • LPA
  • ALDX Strong Buy
  • Analyst Count
  • LPA 0
  • ALDX 2
  • Target Price
  • LPA N/A
  • ALDX $10.00
  • AVG Volume (30 Days)
  • LPA 6.9K
  • ALDX 666.8K
  • Earning Date
  • LPA 03-25-2025
  • ALDX 05-01-2025
  • Dividend Yield
  • LPA N/A
  • ALDX N/A
  • EPS Growth
  • LPA N/A
  • ALDX N/A
  • EPS
  • LPA N/A
  • ALDX N/A
  • Revenue
  • LPA $44,311,428.00
  • ALDX N/A
  • Revenue This Year
  • LPA N/A
  • ALDX N/A
  • Revenue Next Year
  • LPA N/A
  • ALDX N/A
  • P/E Ratio
  • LPA N/A
  • ALDX N/A
  • Revenue Growth
  • LPA 22.46
  • ALDX N/A
  • 52 Week Low
  • LPA $6.00
  • ALDX $2.75
  • 52 Week High
  • LPA $525.00
  • ALDX $7.20
  • Technical
  • Relative Strength Index (RSI)
  • LPA N/A
  • ALDX 53.63
  • Support Level
  • LPA N/A
  • ALDX $6.22
  • Resistance Level
  • LPA N/A
  • ALDX $6.87
  • Average True Range (ATR)
  • LPA 0.00
  • ALDX 0.46
  • MACD
  • LPA 0.00
  • ALDX -0.03
  • Stochastic Oscillator
  • LPA 0.00
  • ALDX 60.51

About LPA Logistic Properties of the Americas

Logistic Properties of the Americas is a fully-integrated, internally managed real estate company that develops, owns and manages a diversified portfolio of warehouse logistics assets in Central America and the South America. It focuses on modern Class A logistics real estate in high growth and high barrier-to-entry markets that are undersupplied and have low penetration rates.

About ALDX Aldeyra Therapeutics Inc.

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Share on Social Networks: